Table 2.

Univariate and multivariate analyses of prognostic factors in BC for 5-year overall survival

	Year	Univariate analysis			Multivariate analysis
		HR	P value	95% CI	HR	P value	95% CI
Expression of MARS
High versus low or no expression	5	4.844	<0.001*	2.154 to 10.893	3.618	0.002*	1.581 to 8.281
Age (years)
≤40 vs 40–60 vs ≥60	5	1.007	0.975	0.652 to 1.555
Tumour grade
I vs II vs III	5	1.539	0.038*	1.026 to 2.474	1.211	0.393	0.781 to 1.879
Tumour size (cm)
≤2 cm vs ＞2 cm	5	1.045	0.886	0.570 to 1.916
Expression of ER
Negative versus positive	5	0.726	0.326	0.384 to 1.375
Expression of PR
Negative versus positive	5	0.726	0.295	0.399 to 1.321
Expression of HER-2
Negative versus positive	5	2.302	0.006*	1.264 to 4.194	0.229	1.458	0.789 to 2.697
Expression of Ki-67
<20% vs ≥20%	5	1272	0.436	0.694 to 2.332
Molecular classification
Luminal A versus luminal B versus HER-2 overexpression versus TNBC	5	1.243	0.115	0.948 to 1.631
Histological type
Ducatl versus lobular versus other	5	0.806	0.705	0.475 to 1.368
N stage
N0 vs N1+2+3	5	1.237	0.492	0.675 to 2.267
TNM stage
I vs II vs III and IV	5	2.648	<0.001*	1.691 to 4.149	2.351	<0.001*	1.460 to 3.786

*p < 0.05.

BC, breast cancer; ER, oestrogen receptor; HER-2, human epidermal growth factor receptor 2; MARS, methionyl–tRNA synthetase; PR, progesterone receptor; TNM, tumour, node, metastasis.